Groupama Asset Managment Purchases 145,799 Shares of GSK plc (NYSE:GSK)

Groupama Asset Managment grew its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 11.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,413,089 shares of the pharmaceutical company's stock after acquiring an additional 145,799 shares during the period. Groupama Asset Managment owned about 0.07% of GSK worth $578,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GSK. Eastern Bank acquired a new position in shares of GSK in the 3rd quarter valued at about $26,000. Concord Wealth Partners boosted its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after buying an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK during the 2nd quarter worth approximately $37,000. Fortitude Family Office LLC bought a new stake in shares of GSK in the 3rd quarter valued at $42,000. Finally, PrairieView Partners LLC acquired a new position in shares of GSK during the 2nd quarter valued at $47,000. Institutional investors own 15.74% of the company's stock.

GSK Price Performance

GSK stock traded down $0.80 during mid-day trading on Tuesday, hitting $35.19. 5,382,868 shares of the stock were exchanged, compared to its average volume of 4,166,355. The business has a fifty day moving average price of $36.56 and a 200 day moving average price of $39.50. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $72.93 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 1.33 and a beta of 0.64.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.47%. The ex-dividend date is Friday, November 15th. This is a positive change from GSK's previous quarterly dividend of $0.38. GSK's payout ratio is 99.35%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a "buy" rating to a "hold" rating and decreased their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com lowered shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 4th. Finally, Barclays raised shares of GSK to a "hold" rating in a research report on Tuesday, August 27th. Seven research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.25.

Insider Activity

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.